Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (481)	12/30/1997 1:01:00 AM
From: Brander	Read Replies (1) \| Respond to of 834

For Novastan clinical trials submitted to the FDA, or any other trial submitted, there is a Methods section, and the FDA reviews this. If the trials for Novastan were not set up appropriatly, the FDA would have demanded that the trials be redone. Novastan would not be this far with the FDA if the studies were not done in a scientific and eithcal manner--Unless you are saying the TXB overtly faked the results, which I seriously doubt. This would have to involve the investigators, and they would not risk their careers and professional reputations as scientists to fake results for TXB. Also, what you are insinuating that TXB has done would result in serioulsy heavy fines and delisting by the American Stock Exh, and I doubt TXB would subject itself to that. I have asked you many times to provide evidence to your serious claims that TXB faked the clinical trials on Novastan, and you have not answered with any supporting evidence. Why? Brad